Option Care Health reported second quarter 2026 net revenue of $1.44 billion, a 1.9% increase year over year, driven by high-single-digit organic growth in its acute therapy portfolio. Adjusted EBITDA rose 3% to $117.5 million, and adjusted EPS increased 9.8% to $0.45, including a $0.03 benefit from share repurchases. The company maintained its full-year revenue guidance of $5.675 billion to $5.775 billion but narrowed its adjusted EBITDA range to $480 million to $495 million and adjusted EPS to $1.85 to $1.92. Management cited stabilization in the chronic inflammatory disease patient census, sequential growth in IG neuro and rare and orphan portfolios, and the addition of five new ambulatory infusion clinics. Option Care Health repurchased $150 million of stock in the quarter, leaving $525 million under its current authorization, and ended with a net debt leverage ratio of 2.1 times.
Option Care Health IncQ2 revenue and EBITDA beat, EPS up 9.8%, and narrowed guidance reflect solid performance and share repurchases.
